MA54985A - Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 - Google Patents
Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1Info
- Publication number
- MA54985A MA54985A MA054985A MA54985A MA54985A MA 54985 A MA54985 A MA 54985A MA 054985 A MA054985 A MA 054985A MA 54985 A MA54985 A MA 54985A MA 54985 A MA54985 A MA 54985A
- Authority
- MA
- Morocco
- Prior art keywords
- bioisostery
- pharmacophores
- mcl
- antagonists
- alpha
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638846P | 2018-03-05 | 2018-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54985A true MA54985A (fr) | 2021-12-29 |
Family
ID=65991891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054985A MA54985A (fr) | 2018-03-05 | 2019-03-04 | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11274105B2 (fr) |
| EP (1) | EP3762393B1 (fr) |
| MA (1) | MA54985A (fr) |
| WO (1) | WO2019173181A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3036998T3 (en) | 2017-08-18 | 2025-09-26 | Amgen Inc | Compounds that inhibit mcl-1 protein |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
| US10703733B2 (en) | 2018-05-14 | 2020-07-07 | Gilead Sciences, Inc. | MCL-1 inhibitors |
| CN112479876B (zh) * | 2019-09-12 | 2023-07-21 | 苏州亚盛药业有限公司 | 氧氮杂环庚烷类螺环化合物、中间体及其制备方法 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US11325891B2 (en) | 2019-11-26 | 2022-05-10 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| WO2021225835A1 (fr) * | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthèse d'intermédiaires d'alcool vinylique |
| WO2021250102A1 (fr) | 2020-06-10 | 2021-12-16 | Janssen Pharmaceutica Nv | 2-amino-3-fluoro-but-3-énamides macrocycliques utilisés comme inhibiteurs de mcl-1 |
| US12202782B2 (en) | 2020-11-19 | 2025-01-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| JP2023554070A (ja) | 2020-12-17 | 2023-12-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての分岐３－フルオロ－ブタ－３－エナミド |
| ES3017082T3 (en) | 2021-04-26 | 2025-05-12 | Janssen Pharmaceutica Nv | Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1 |
| EP4351564A1 (fr) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 en combinaison avec des agents anticancéreux |
| CA3222752A1 (fr) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 en combinaison avec des conjugues anti-corps-medicament |
| US20250051359A1 (en) | 2021-11-16 | 2025-02-13 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| CA2682356C (fr) | 2007-04-16 | 2016-06-14 | Abbott Laboratories | Inhibiteurs mcl-1 indole 7-substitues |
| EP2528893B1 (fr) | 2010-01-29 | 2018-10-10 | Dana-Farber Cancer Institute, Inc. | Petites molécules pour la modulation de mcl-1 et procédés de modulation de la mort cellulaire, la division cellulaire, la différenciation cellulaire et procédés de traitement de troubles |
| WO2013052943A2 (fr) | 2011-10-06 | 2013-04-11 | The Regents Of The University Of Michgian | Inhibiteurs à petite molécule de mcl-1 et leurs utilisations |
| US9914723B2 (en) | 2012-03-29 | 2018-03-13 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and uses thereof |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| ES3036998T3 (en) | 2017-08-18 | 2025-09-26 | Amgen Inc | Compounds that inhibit mcl-1 protein |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
-
2019
- 2019-03-04 MA MA054985A patent/MA54985A/fr unknown
- 2019-03-04 EP EP19714512.1A patent/EP3762393B1/fr active Active
- 2019-03-04 WO PCT/US2019/020492 patent/WO2019173181A1/fr not_active Ceased
- 2019-03-04 US US16/977,527 patent/US11274105B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210047344A1 (en) | 2021-02-18 |
| WO2019173181A1 (fr) | 2019-09-12 |
| EP3762393A1 (fr) | 2021-01-13 |
| EP3762393B1 (fr) | 2023-01-11 |
| US11274105B2 (en) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54985A (fr) | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 | |
| EP3721409A4 (fr) | Détection d'activité par détection et suivi conjoints d'homme et d'objet | |
| MA51747A (fr) | Formulation d'anticorps pharmaceutique à ph faible | |
| EP4062373C0 (fr) | Analyse spatiale d'analytes | |
| PL3761980T3 (pl) | Związki aminokwasowe i sposoby zastosowania | |
| MA51620A (fr) | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques | |
| EP4025908A4 (fr) | Dosage d'anticorps anti-médicament | |
| EP3938077A4 (fr) | Analyseur de concentration de point d'intervention | |
| EP3811962A4 (fr) | Formulation liquide aqueuse contenant des protéines | |
| MA51998A (fr) | Nouveaux polymorphes de sel de calcium en tant qu'agents anti-inflammatoires, immunomodulateurs et anti-prolifératifs | |
| MA54052A (fr) | Formulation d'anticorps | |
| EP3621640A4 (fr) | Constructions d'anticorps d'acide nucléique optimisées | |
| MA46863A (fr) | Administration intrathécale de virus adéno-associé recombinant codant pour la protéine 2 de liaison méthyl-cpg | |
| EP3488018A4 (fr) | Procédés et compositions pour l'identification de protéines | |
| EP3912989A4 (fr) | Peptide pénétrant basé sur la protéine m2 du virus de la grippe | |
| EP3508200A4 (fr) | Formulation aqueuse contenant de l'acide 5-aminolévulinique ou similaire | |
| MA45921A (fr) | Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine. | |
| MA43685A (fr) | Solutions aqueuses d'acides aminés n-acylés | |
| EP3849612A4 (fr) | Variants d'anticorps anti-vih 10-1074 | |
| EP3414256A4 (fr) | Sel d'amine de l'acide obéticholique | |
| EP3859332A4 (fr) | Procédé de dosage d'hémoglobine glyquée (%) | |
| MA51681A (fr) | Anticorps humains contre l'hémagglutinine de la grippe | |
| FR3051693B1 (fr) | Reseau d'elements transducteurs ultrasonores | |
| EP3924507A4 (fr) | Cartographie quantitative de protéines associées à la chromatine | |
| EP3844180A4 (fr) | Circuits de protéine synthétique permettant de détecter une activité de transducteur de signal |